The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease

被引:284
作者
Brewster, UC [1 ]
Perazella, MA [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA
关键词
D O I
10.1016/j.amjmed.2003.09.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The renin-angiotensin-aldosterone system regulates renal vasomotor activity, maintains optimal salt and water homeostasis, and controls tissue growth in the kidney. However, pathologic consequences can result from overactivity of this cascade, involving it in the pathophysiology of kidney disease. An activated renin-angiotensin-aldosterone system promotes both systemic and glomerular capillary hypertension, which can induce hemodynamic injury to the vascular endothelium and glomerulus. In addition, direct profibrotic and proinflammatory actions of angiotensin II and aldosterone may also promote kidney damage. The majority of the untoward effects associated with angiotensin II appear to be mediated through its binding to the angiotensin II type I receptor. Aldosterone can also induce re-nal injury by binding to its receptor in the kidney. An understanding of this system is important to appreciate that inhibitors of this cascade can reduce the progression of chronic kidney disease in proteinuric disease states. Pharmacologic agents that can interfere with this cascade include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists. This paper will provide an over-view of the renin-angiotensin system, review its role in kidney disease, examine the renal effects of inhibition of this cascade in experimental animal models, and review clinical studies utilizing renin-angiotensin-aldosterone inhibitors in patients with diabetic and nondiabetic nephropathies.(C)2004 by Excerpta Medica Inc.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 70 条
  • [11] Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
    Chrysostomou, A
    Becker, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 925 - 926
  • [12] Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes
    Duncan, JA
    Scholey, JW
    Miller, JA
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (01) : 111 - 116
  • [13] TISSUE ANGIOTENSIN SYSTEM IN CARDIOVASCULAR MEDICINE - A PARADIGM SHIFT
    DZAU, VJ
    RE, R
    [J]. CIRCULATION, 1994, 89 (01) : 493 - 498
  • [14] DZAU VJ, 1994, J HYPERTENS S4, V12, P3
  • [15] Eplerenone reduces proteinuria in type II diabetes mellitus: Implications for aldosterone involvement in the pathogenesis of renal dysfunction
    Epstein, M
    Buckalew, V
    Altamirano, J
    Roniker, B
    Krause, S
    Kleiman, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 249A - 249A
  • [16] ANGIOTENSIN-I CONVERTING ENZYME AND THE CHANGES IN OUR CONCEPTS THROUGH THE YEARS - DAHL,LEWIS,K. MEMORIAL LECTURE
    ERDOS, EG
    [J]. HYPERTENSION, 1990, 16 (04) : 363 - 370
  • [17] Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
    Feria, I
    Pichardo, I
    Juárez, P
    Ramírez, V
    González, MA
    Uribe, N
    García-Torres, R
    López-Casillas, F
    Gamba, G
    Bobadilla, NA
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (01) : 43 - 52
  • [18] GARTY H, 1992, SEMIN NEPHROL, V12, P24
  • [19] GARVIN JL, 1991, J AM SOC NEPHROL, V1, P1146
  • [20] Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent
    Griffin, KA
    Abu-Amarah, I
    Picken, M
    Bidani, AK
    [J]. HYPERTENSION, 2003, 41 (02) : 201 - 206